RBBP4 and breast carcinoma: Inhibition of RBBP4-BCL11A complex formation by BCL11A peptide inhibitor may decrease aldehyde dehydrogenase-positive breast cancer stem cells; hence, targeting interactions between RBBP4 and oncogenic transcription factors may provide opportunities for intervention (Moody et al., 2018).